Impacts on quality of life with escitalopram monotherapy and aripiprazole augmentation in patients with major depressive disorder: A CAN-BIND report
E Morton, V Bhat, P Giacobbe, W Lou… - …, 2021 - thieme-connect.com
Introduction Many individuals with major depressive disorder (MDD) do not respond to initial
antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non …
antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non …
Predictors of quality of life improvement with escitalopram and adjunctive aripiprazole in patients with major depressive disorder: A CAN-BIND study report
Background Non-response to first-line treatment for major depressive disorder (MDD) is
common; for such individuals, quality of life (QoL) impairments can be severe. Identifying …
common; for such individuals, quality of life (QoL) impairments can be severe. Identifying …
[HTML][HTML] Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term …
TJ Fabian, ZJ Cain, D Ammerman… - The Primary Care …, 2012 - psychiatrist.com
Objective: To evaluate the effect of adjunctive aripiprazole to antidepressant therapy (ADT)
on functional outcomes, as assessed by the Sheehan Disability Scale (SDS). Method: A post …
on functional outcomes, as assessed by the Sheehan Disability Scale (SDS). Method: A post …
Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with …
SH Kennedy, RW Lam, S Rotzinger… - The Journal of …, 2019 - psychiatrist.com
Objective: To report the symptomatic and functional outcomes in patients with major
depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of …
depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of …
[HTML][HTML] Cognitive and psychosocial improvements following aripiprazole augmentation of SSRI antidepressant therapy in treatment refractory depression: a pilot …
TL Greer, P Sunderajan, BD Grannemann… - Open Journal of …, 2013 - scirp.org
Functional impairments are a common concern for individuals with major depressive
disorder (MDD) that does not resolve with initial antidepressant treatment. Such concerns …
disorder (MDD) that does not resolve with initial antidepressant treatment. Such concerns …
Cognitive outcomes with sequential escitalopram monotherapy and adjunctive aripiprazole treatment in major depressive disorder: a Canadian biomarker integration …
Background Cognitive deficits are detectable in major depressive disorder (MDD). The
cognitive impact of antidepressants remains unclear, as does the cognitive effects of …
cognitive impact of antidepressants remains unclear, as does the cognitive effects of …
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants
RM Berman, M Fava, ME Thase, MH Trivedi… - CNS …, 2009 - cambridge.org
Introduction: Effective management of major depressive disorder (MDD) continues to be a
challenging task for psychiatrists and primary care physicians. This trial evaluated the …
challenging task for psychiatrists and primary care physicians. This trial evaluated the …
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized …
Y Wang, Z Lu, G Xun - Journal of Affective Disorders, 2024 - Elsevier
Objectives To explore the effect of escitalopram combined with aripiprazole on cognitive
function in patients with major depressive disorder (MDD), and to evaluate the clinical …
function in patients with major depressive disorder (MDD), and to evaluate the clinical …
Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major …
SF Smagula, ML Wallace, SJ Anderson, JF Karp… - Journal of psychiatric …, 2016 - Elsevier
Personalizing treatment for late-life depression requires identifying and integrating
information from multiple factors that influence treatment efficacy (moderators). We …
information from multiple factors that influence treatment efficacy (moderators). We …
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
CW Espinola, Y Khoo, R Parmar… - Brain and …, 2022 - Wiley Online Library
Objective To report side effect frequency and severity in patients with major depressive
disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine …
disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine …
相关搜索
- impacts on quality aripiprazole augmentation
- bind 1 aripiprazole therapy
- life improvement adjunctive aripiprazole
- predictors of quality adjunctive aripiprazole
- predictors of quality life improvement
- aripiprazole augmentation inadequate response
- early prediction aripiprazole therapy
- aripiprazole augmentation clinical profiles
- quality of life aripiprazole augmentation